JPH01262860A - Cornea protecting agent - Google Patents
Cornea protecting agentInfo
- Publication number
- JPH01262860A JPH01262860A JP63089139A JP8913988A JPH01262860A JP H01262860 A JPH01262860 A JP H01262860A JP 63089139 A JP63089139 A JP 63089139A JP 8913988 A JP8913988 A JP 8913988A JP H01262860 A JPH01262860 A JP H01262860A
- Authority
- JP
- Japan
- Prior art keywords
- cornea
- contact lens
- solidified body
- solidified
- wearing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004087 cornea Anatomy 0.000 title abstract description 24
- 239000003223 protective agent Substances 0.000 title 1
- 229920000642 polymer Polymers 0.000 claims abstract description 6
- 150000004676 glycans Chemical class 0.000 claims description 11
- 229920001282 polysaccharide Polymers 0.000 claims description 11
- 239000005017 polysaccharide Substances 0.000 claims description 11
- 239000003795 chemical substances by application Substances 0.000 abstract description 6
- 229920002385 Sodium hyaluronate Polymers 0.000 abstract description 3
- 239000000872 buffer Substances 0.000 abstract description 3
- 239000003814 drug Substances 0.000 abstract description 3
- 229940010747 sodium hyaluronate Drugs 0.000 abstract description 3
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 abstract description 3
- 230000006378 damage Effects 0.000 abstract description 2
- 210000000695 crystalline len Anatomy 0.000 abstract 7
- 210000000981 epithelium Anatomy 0.000 abstract 3
- 229940079593 drug Drugs 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 239000010408 film Substances 0.000 description 5
- 239000003889 eye drop Substances 0.000 description 4
- 229940012356 eye drops Drugs 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- 229920002101 Chitin Polymers 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 210000003560 epithelium corneal Anatomy 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 210000001179 synovial fluid Anatomy 0.000 description 2
- 229920001661 Chitosan Polymers 0.000 description 1
- 241000199223 Elaeocarpus kirtonii Species 0.000 description 1
- 235000009414 Elaeocarpus kirtonii Nutrition 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- 235000013584 Tabebuia pallida Nutrition 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000008378 epithelial damage Effects 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000002265 redox agent Substances 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Materials For Medical Uses (AREA)
Abstract
Description
【発明の詳細な説明】
１産業上の利用分野１
本発明の高分子−多ｔ１類含有凝固体はヒ！・角膜の保
護、治療のための医療に関する。DETAILED DESCRIPTION OF THE INVENTION 1. Industrial Application Field 1 The polymer-multi-t1 type-containing coagulated material of the present invention is available in Hi!・Related to medical care for the protection and treatment of the cornea.
ｌ従来技術の説明１
従来、視力矯正用コンタクトレンズ装用りはコンタクト
レンズ装着時に点眼ｌ＾を介して、或いはコンタクトレ
ンズ洗浄後、直接角膜［−に：コンタクトレンズを装用
している。 また角膜１皮創傷治療には点眼液を用いて
いる。Description of the Prior Art 1 Conventionally, contact lenses for vision correction have been worn either through eye drops when wearing the contact lenses, or directly on the cornea after cleaning the contact lenses. In addition, eye drops are used to treat corneal skin wounds.
［解決しようとする問題点１
しかし、コンタクトレンズ装用りの一部に角膜上皮の損
傷や剥離に伴う痛みや炎症があることが報告されている
。 それは装用者のコンタク！・レンズの角膜との着脱
時に起こる。 つまり、現在使われているソフトコンタ
クトレンズはＮｌｋ性であり 涙１αの少ないとき、角
膜に吸着しやすいためといわれている。[Problem to be Solved 1] However, it has been reported that some contact lens wearers cause pain and inflammation due to damage and detachment of the corneal epithelium. It's the wearer's contacts! - Occurs when the lens is attached to and removed from the cornea. In other words, the soft contact lenses currently in use are said to have Nlk properties, which is said to be because they tend to adhere to the cornea when tear 1α is low.
この様な角膜上皮損傷が起こった場合、コンタクトレン
ズ洗浄後
療に点眼薬が必要となる場合がある。When such corneal epithelial damage occurs, eye drops may be required for treatment after contact lens cleaning.
この点眼薬も涙ｌｌにより流失が早く、角膜トに停まる
時間が短い。This eye drop also washes away quickly due to lachrymal fluid, and stays on the cornea for a short time.
し問題点を解決する１段１
損傷した角膜」上皮の保護や治療を行）ために高分子多
糖類含有凝固体で角膜を覆う。Step 1 to solve the problem: To protect and treat damaged corneal epithelium, cover the cornea with a coagulum containing a polymeric polysaccharide.
つまり、コンタクトレンズと角膜表面との緩衝剤として
高分子多糖類含有凝固体を用いる。That is, a polymeric polysaccharide-containing coagulate is used as a buffer between the contact lens and the corneal surface.
これはコンタクトレンズ凹面と角１模が直接接触するの
を防ぐ。This prevents direct contact between the concave surface of the contact lens and the corner 1 pattern.
「実施例」
天然高分り多糖類で生体適合性があり、医薬品として用
いられているものに、キチンやヒアルロン酸がある
これらは人の血ｌ＆中にも多鼠にあるＮ−アセチルグル
コサミンで構成されている。 このため人体の拒−７反
応はほとんど無い。 キチンは一部、脱アセナル化する
ことおより、多１］！類ｌ１１合１勿キトサンを得、こ
のン８１＾を製膜してフィルム状とし１人口皮膚として
いる。 また、ヒアルロン酸はを椎動物の結合組織の中
でも請帯、関節液および給子体に高濃度で存在する。
この医薬品としてその粘弾性、保水性、透明性を持つ生
体高分子化合物としての高１度のヒアルロン酸ナトリウ
ム溶ｌ＾は、１」節治療剤および、眼科医の前眼部手術
浦助削となっている。 そしてより高ｔ？４度で製膜化
、固形化したヒアルロン酸ナトリウムは主にｔ麦眼部で
の＃ｉＩ膜剥離の治療や水晶体嚢の浦修剤としての利用
が試みられている。"Example" Chitin and hyaluronic acid are natural high-density polysaccharides that are biocompatible and used as pharmaceuticals.
These are composed of N-acetylglucosamine, which is also found in human blood. Therefore, there is almost no rejection reaction in the human body. Part of chitin is deasenalized, so it's more likely than not! Chitosan of type 111 was obtained, and this material was formed into a film to form an artificial skin. In addition, hyaluronic acid is present in high concentrations in the connective tissues of vertebrates, such as the ligament, synovial fluid, and synovial fluid.
As a pharmaceutical product, this high-grade sodium hyaluronate solution, which is a biopolymer compound with viscoelasticity, water retention, and transparency, is used as a 1'' treatment agent and as a surgical treatment for the anterior segment of the eye by ophthalmologists. It has become. And higher t? Sodium hyaluronate, which has been formed into a film and solidified at 4 degrees, has been used mainly for the treatment of #iI membrane detachment in the eye area and as a lens capsule repair agent.
本発明ではこれら高分子多糖類含有凝固体を角膜上に間
隙をもってｌＩｔ屓できる形状にしたものである。 角
膜の表面を一般的に曲率半径８ミリメートルはどの球状
の一部円形表面とみなすと、それを高分子″９糖頌３在
凝固膜でＮ−ｌには１ｉｉ１ ｌ二くこの凝固膜を曲面
にしなくてはならない。In the present invention, these polymeric polysaccharide-containing coagulates are shaped so that they can be placed on the cornea with a gap. If the surface of the cornea is generally considered to be a partially circular surface with a radius of curvature of 8 mm, then it is a coagulated film containing a polymer "9 sugars", and N-l is 1ii1 l, and this coagulated film is a curved surface. must be done.
本発明では実施例の一つとして品分子多１１Ａ ２１１
τイ１凝固体を平らな薄膜とし、これを渦巻き状にＬｌ
ｌ抜き、どの様な曲率半径をもつ曲面にも接着しやすく
しようとしたものである。In the present invention, as one of the embodiments, the product molecular number 11A 211
τa1 The solidified material is made into a flat thin film, and this is spirally formed into Ll.
This is intended to make it easier to adhere to curved surfaces with any radius of curvature.
なお、本発明の高分子多糖類含有凝固体は、睨））に及
ばず影響が少ない。 それは凝固体白木か水の屈折・Ｆ
に近く出来、ｆｌＪＩ模１−に装置１１シた時、涙Ｉα
の水分を３み凝固体と涙ｌ＾との境界が鮮明ではなくな
り、短時間で慣れる。 そのＦ、Ｉな屈折はコンタクト
レンズと角膜が行うため、変形、溶解、流失の理由で視
力は大きくは変化しない。In addition, the polymeric polysaccharide-containing coagulate of the present invention has less influence than 2)). Is it solidified white wood or water refraction/F?
It was close to that, and when I put the device 11 on flJI model 1-, I was in tears.
The boundary between the coagulated body and the lachrymal fluid becomes less clear, and you get used to it in a short time. Since the F and I refraction is performed by the contact lens and the cornea, visual acuity does not change significantly due to deformation, dissolution, or loss.
この高分子多糖類含有凝固体の形状として、渦巻状の他
に多重円状、星秋などの円状や放Ｑ、ｔ 、Ｉｊことし
ても＋ｉｉｆ述した様にどの様な曲率半径をもつｆｒ＋
Ｉ膜面にも適合出来る。The shape of this polymeric polysaccharide-containing coagulate may be a spiral shape, a multicircular shape, a circular shape such as a starry fall, or a fr+ with any radius of curvature as described above.
It can also be adapted to I-film surfaces.
第一図は本発明の詳細な説明する為の渦巻状になった高
分ｆｔ糖類含有凝固体Ｈの正面図である。 第二［では
本発明の詳細な説明する／）の渦巻状になった高分子多
糖類Ｘ１１凝固体１１が角ＩＩ！ Ａとコンタクトレン
ズＣとのｔｌＵｍ削とな−）でいる断面図である。FIG. 1 is a front view of a coagulated mass H containing high-fat sugars in a spiral shape for explaining the present invention in detail. The second [detailed explanation of the present invention/) spiral-shaped coagulated polymer polysaccharide X11 11 is the corner II! FIG. 2 is a cross-sectional view of contact lens A and contact lens C at tlUm cutting.
第一図において１本発明の凝固体Ｂは渦巻状であるので
間隙りが設けられる。 つまり、第一図において、１６
Ｉ模ＡとコンタクトレンズＣとの １間の緩衡剤Ｂの
凝固体は渦巻状であるので間隙りが設けられる。 ここ
では涙液や薬液の滞留が出来る。なお、高′Ｊ″ＥＦ多
糖類は超音波、紫外線、熱などの機械的作用や酸化還元
剤やヒアルロニダーゼなどの化７作用により紙分１′化
される。 本発明の品分イＳ糖墳含有凝固体は角膜上で
変形、溶解、流出しても良く、一定時間。In FIG. 1, since the solidified body B of the present invention has a spiral shape, a gap is provided. In other words, in Figure 1, 16
Since the coagulated body of buffering agent B between I model A and contact lens C is spiral-shaped, a gap is provided. Tears and medicine can accumulate here. In addition, the high 'J'' EF polysaccharide is converted to paper content by mechanical action such as ultrasonic waves, ultraviolet rays, and heat, and chemical action of redox agents and hyaluronidase. The contained coagulum may be deformed, dissolved, or flowed out on the cornea for a certain period of time.
角膜とコンタクトレンズのｖＬ街剤となっていれば良い
、 この凝固体の角膜上への装着は、＝１ンタクトレン
ズの凹面にこの凝固体を押しｌ＝ｔけ、コンタクトレン
ズと共に角膜上に装着すると簡便である。It is sufficient that the coagulate is a VL agent between the cornea and the contact lens.To attach this coagulate onto the cornea, press the coagulate onto the concave surface of the contact lens and attach it on the cornea together with the contact lens. Then it is convenient.
［発明の効果［
以［説明したように本発明の高分子多糖類Ｘ１１凝固体
を＝１ンタクトレンズと角膜との間に緩衝剤として装用
することにより角膜上皮ｆｉｌ ＩｔｓをＩＩＪｊぐこ
とはもちろん、角１漠１−皮損傷時の：１ンタクトレン
ズの継続装用をｉｉ（能にすることができる。[Effects of the Invention] [As explained below, by applying the polymeric polysaccharide Continuous wearing of contact lenses can be made possible when skin damage occurs.
第一図は本発明を説明するための品分１′−を抛類含ａ
凝固体よりなる角膜保護剤の一実施例を示す正面１−Ａ
である。
第二［４はその本発明の角膜保護剤が角膜１−でａ術前
となっていることをｊｌ！明するための断面１−イ１で
ある。
持許出願友 ト￥多 シ１代１−１
口面
第１因Figure 1 includes items 1'-A for explaining the present invention.
Front view 1-A showing an example of a corneal protectant made of a coagulate
It is. The second [4] indicates that the corneal protectant of the present invention is applied to the cornea 1- before surgery. This is a cross section 1--1 for clarification. Permanent applicant friend To ¥ 3 Shi 1 generation 1-1 Oral first factor
Claims (1)
をもつて覆う形状にした事を特徴とする高分子多糖類含
有凝固体よりなる角膜保護剤。1. A corneal protectant comprising a polymer polysaccharide-containing coagulate, characterized in that the polymer polysaccharide-containing coagulum has a spherical shape that covers a partially circular surface with gaps.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP63089139A JPH01262860A (en) | 1988-04-13 | 1988-04-13 | Cornea protecting agent |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP63089139A JPH01262860A (en) | 1988-04-13 | 1988-04-13 | Cornea protecting agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH01262860A true JPH01262860A (en) | 1989-10-19 |
Family
ID=13962540
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP63089139A Pending JPH01262860A (en) | 1988-04-13 | 1988-04-13 | Cornea protecting agent |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH01262860A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU697739B2 (en) * | 1994-03-14 | 1998-10-15 | Seikagaku Corporation | Material to be worn on the eyeball |
-
1988
- 1988-04-13 JP JP63089139A patent/JPH01262860A/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU697739B2 (en) * | 1994-03-14 | 1998-10-15 | Seikagaku Corporation | Material to be worn on the eyeball |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3662253B2 (en) | Eye mounting material | |
| JP4755795B2 (en) | Method for producing hyaluronic acid gel and medical material containing the same | |
| EP0763754B1 (en) | Photocured crosslinked-hyaluronic acid contact lens | |
| TWI288630B (en) | Vision enhancing ophthalmic devices and related methods and compositions | |
| AU694628B2 (en) | Bio-erodible ophthalmic shield | |
| US4365050A (en) | Amino-polysaccharides and copolymers thereof for contact lenses and ophthalmic compositions | |
| JP2012083750A (en) | Contact lens package solution | |
| JPS6145608B2 (en) | ||
| WO2000027405A1 (en) | Hyaluronic acid gel, process for the preparation thereof and medical materials containing the same | |
| JP4006039B2 (en) | Photocrosslinked hyaluronic acid contact lens | |
| Aquavella et al. | Therapeutic applications of a collagen bandage lens: A preliminary report | |
| JPH01262860A (en) | Cornea protecting agent | |
| KR20160060227A (en) | Composition for preventing or treating eye disease | |
| AU5454594A (en) | Ophthalmic solution and method of use | |
| JPH01279836A (en) | Remedy for cornea | |
| AQUAVELLA | Therapeutic uses of hydrophilic lenses | |
| JP5461468B2 (en) | Method for producing hyaluronic acid gel and medical material containing the same | |
| EP3512572B1 (en) | Adhesive biopolymer as a temporary epithelium substitute | |
| RU2098079C1 (en) | Eyegel | |
| Devi et al. | Significance of hyaluronic acid in the biomedical field: A review | |
| KR20230080853A (en) | pH-responsive hydrogel contact lens for drug delivery and manufacturing method thereof | |
| Aquavella | The Soft Contact Lens I: Therapeutic Experience With the Softcon Lens | |
| JPH04176459A (en) | Wound treating material of eye comprising chitin film | |
| Woodward | Contact lenses | |
| KR20020036881A (en) | Soft Intraocular Lens and Process |